关键词:

冠心病, 心力衰竭, 补中益气汤, 血府逐瘀汤, 临床研究

Abstract:

Objective　To evaluate the efficacy and safety of Buzhong Yiqi Decoction combined with Xuefu Zhuyu Decoction in treating patients with coronary heart disease (CHD) and heart failure (HF). Methods　This was a retrospective study. A total of 140 patients with CHD and HF admitted to the Department of Cardiology, Tongchuan Hospital of Traditional Chinese Medicine from January 2022 to June 2023 were selected and were divided into a control group and a treatment group according to different treatment methods. In the control group of 68 cases, there were 36 males and 32 females, the age was (58.31±8.07) years, and the course of disease was (6.55±3.07) years. In the treatment group of 72 cases, there were 37 males and 35 females, the age was (60.42±7.98) years, and the course of disease was (7.27±2.37) years. The control group received standard cardiology treatment, and the treatment group received Buzhong Yiqi Decoction and Xuefu Zhuyu Decoction on the basis of standard cardiology treatment, 200 ml was taken warmly after breakfast and dinner, 1 dose a day, 7 days as a course of treatment. The efficacy was evaluated in both groups after continuous treatment for 12 weeks. The efficacy evaluation indicators included the New York Heart Association (NYHA) cardiac function grade, left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), and 6 min walking distance, heart rate, C-reactive protein, N-terminal pro B-type natriuretic peptide (NT-proBNP), quality of life score, and incidence of adverse reactions. χ² test and t test were used for statistical analysis. Results　After 12 weeks of treatment, the total effective rate was 91.67% (66/72) in the treatment group and 75.00% (51/68) in the control group, with a statistically significant difference (χ²=5.914, P=0.015). In the treatment group, the LVEF, LVESD, and LVEDD were (58.32±9.78)%, (40.67±6.01) mm, and (45.10±6.69) mm, and the above indexes in the control group were (47.67±8.98)%, (48.52±7.47) mm, and (54.31±8.08) mm, with statistically significant differences (t=-6.700, 6.869, and 7.363, all P<0.001). In the treatment group, the 6 min walking distance, heart rate, C-reactive protein, and NT-proBNP were (320.36±28.09) m, (73.31±13.52) beats/min, (4.25±1.21) mg/L, and (301.67±44.45) µg/L, and the above indexes in the control group were (290.58±21.31) m, (82.41±10.44) beats/min, (7.31±3.65) mg/L, and (378.32±36.79) µg/L, with statistically significant differences (t=-7.036, 4.439, 6.734, and 11.080, all P<0.001). The scores of physiological, psychological, environmental, and social relations in the treatment group were higher than those in the control group (all P<0.05). During the treatment period, the incidence of adverse reactions was 12.50% (9/72) in the treatment group and 13.24% (9/68) in the control group, without statistically significant difference (χ²=0.124, P=0.971). Conclusions　Buzhong Yiqi Decoction and Xuefu Zhuyu Decoction have obvious advantages in improving the heart function and quality of life in patients with CHD and HF, with good safety. 

Key words:

Coronary heart disease, Heart failure, Buzhong Yiqi , Decoction, Xuefu Zhuyu , Decoction, Clinical study